```html

Drug‑Induced Hepatotoxicity

Overview

Drug‑induced hepatotoxicity (DIH) refers to liver injury that occurs as an adverse reaction to prescription medications, over‑the‑counter (OTC) drugs, herbal supplements, or illicit substances. The liver is the body’s primary detoxification organ; when it is overwhelmed or damaged by a toxic agent, enzymes leak into the bloodstream and liver function declines.

DIH can affect anyone who takes a medication, but certain groups are more vulnerable:

• Older adults (polypharmacy is common)
• Patients with pre‑existing liver disease (e.g., hepatitis B/C, non‑alcoholic fatty liver disease)
• People with genetic polymorphisms affecting drug metabolism (e.g., CYP450 variants)
• Women—some studies show a modestly higher risk for idiosyncratic reactions

While exact prevalence varies by region and drug class, large epidemiologic studies estimate that 1–2% of all hospitalizations for acute liver injury are attributable to medications, and up to 10% of chronic liver disease cases have a drug‑related component.

Symptoms

Symptoms of drug‑induced hepatotoxicity range from subtle to life‑threatening. They often mirror other liver disorders, so a high index of suspicion is essential when a new drug is started.

• Fatigue & Weakness – often the first, nonspecific sign.
• Right Upper Quadrant (RUQ) Discomfort – dull ache or fullness under the ribs.
• Jaundice – yellowing of the skin and sclerae due to elevated bilirubin.
• Dark Urine – presence of bilirubin excreted in urine.
• Pale, Clay‑Colored Stools – lack of bile pigments.
• Pruritus (Itching) – caused by bile salt accumulation.
• Nausea, Vomiting, or Anorexia – loss of appetite and gastrointestinal upset.
• Abdominal Swelling (Ascites) – in severe or chronic cases.
• Confusion or Asterixis – signs of hepatic encephalopathy.
• Fever – may indicate an immune‑mediated drug reaction.
• Erythema or Rash – especially with hypersensitivity syndromes.

Causes and Risk Factors

Common Culprit Drugs

More than 1,000 agents have been implicated in DIH. The most frequently reported categories include:

• Acetaminophen (Paracetamol) – overdose is the leading cause of acute liver failure in the U.S. (CDC).
• Antibiotics – e.g., amoxicillin‑clavulanate, isoniazid, fluoroquinolones.
• Antiepileptics – phenytoin, carbamazepine, valproic acid.
• Statins – especially high‑dose simvastatin.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – diclofenac, ibuprofen (rare but documented).
• Herbal/Dietary Supplements – kava, green tea extract, pennyroyal oil.
• Immunosuppressants – methotrexate, azathioprine.
• Antifungals – ketoconazole, itraconazole.

Mechanisms of Injury

• Direct Toxicity – dose‑dependent injury (e.g., acetaminophen). Metabolic by‑products damage hepatocytes.
• Idiosyncratic Reaction – unpredictable, not dose‑related; often immune‑mediated.
• Metabolic Interaction – inhibition/induction of cytochrome P450 enzymes leading to accumulation of a toxic metabolite.
• Mitochondrial Dysfunction – especially with valproic acid and certain antiretrovirals.

Patient‑Specific Risk Factors

• Age > 65 years
• Female sex (higher rates of idiosyncratic reactions)
• Pre‑existing liver disease (viral hepatitis, NAFLD, cirrhosis)
• Alcohol use (>20 g/day for women, >30 g/day for men)
• Genetic polymorphisms (e.g., CYP2E1, HLA‑B*57:01)
• Concurrent use of multiple hepatotoxic drugs
• Obesity and metabolic syndrome

Diagnosis

Diagnosing DIH is a process of exclusion—ruling out viral hepatitis, autoimmune hepatitis, alcoholic liver disease, and biliary obstruction.

History & Physical Examination

• Detailed medication list (prescribed, OTC, supplements) with start dates.
• Temporal relationship between drug exposure and symptom onset.
• Risk factor assessment (alcohol, viral hepatitis status, etc.).
• Physical signs: jaundice, hepatomegaly, ascites, encephalopathy.

Laboratory Tests

Test	What It Shows
ALT (Alanine aminotransferase)	Hepatocellular injury; values >5× ULN are suspicious.
AST (Aspartate aminotransferase)	Often parallels ALT but also in muscle injury.
Alkaline Phosphatase (ALP)	Cholestatic pattern; high in biliary obstruction.
Bilirubin (Total & Direct)	Elevated in jaundice; >2 mg/dL is clinically significant.
Gamma‑Glutamyl Transferase (GGT)	Supports drug‑related cholestasis.
Prothrombin Time / INR	Assess synthetic function; >1.5 suggests severe injury.
Serum ammonia	Elevated in hepatic encephalopathy.
Autoimmune panel (ANA, ASMA)	To rule out autoimmune hepatitis.
Viral hepatitis serologies	HBV, HCV, HAV, HEV.

Imaging

• Ultrasound – first‑line to exclude biliary obstruction or focal lesions.
• CT or MRI – reserved for complex cases or when transplant is considered.

Scoring Systems

The RUCAM (Roussel Uclaf Causality Assessment Method) assigns points based on timing, risk factors, course after drug withdrawal, and other causes. Scores ≥6 indicate “probable” drug‑induced injury.

Treatment Options

Treatment is aimed at stopping the offending agent, supporting liver regeneration, and managing complications.

Immediate Steps

1. Discontinue the suspected drug as soon as DIH is suspected.
2. Provide acetylcysteine for acetaminophen toxicity—most effective within 8 hours of overdose.
3. Hospital admission if: ALT/AST > 1,000 IU/L, INR > 1.5, bilirubin > 3 mg/dL, or encephalopathy.

Medication‑Specific Antidotes & Therapies

• N‑acetylcysteine (NAC) – antidote for acetaminophen; also used in non‑acetaminophen acute liver failure.
• Corticosteroids – considered for immune‑mediated DIH (e.g., with drug‑induced autoimmune hepatitis).
• Ursodeoxycholic acid – may help cholestatic injury from certain antibiotics.

Supportive Care

• IV fluids to maintain perfusion.
• Nutrition: high‑protein, low‑fat diet; consider enteral feeding if oral intake is poor.
• Monitoring for hypoglycemia, coagulopathy, and encephalopathy.
• Vitamin K administration for coagulopathy (unless contraindicated).

Procedures

• Liver transplant – indicated for acute liver failure with worsening encephalopathy, INR > 2, or multiorgan failure.
• Therapeutic plasma exchange – emerging adjunct in severe cases.

Long‑Term Management

• Regular liver function tests (LFTs) every 1–3 months until normalization.
• Avoid re‑exposure to the offending drug and cross‑reactive agents.
• Vaccination against hepatitis A & B if not immune.

Living with Drug‑Induced Hepatotoxicity

Daily Management Tips

• Medication Log – keep a written or app‑based list of every drug and supplement.
• Adherence to Follow‑up – attend scheduled lab appointments; early detection of relapse.
• Hydration – aim for 2–3 L of water daily unless fluid‑restricted.
• Balanced Diet – fruits, vegetables, lean protein; limit saturated fat and simple sugars.
• Avoid Alcohol – even modest intake can impede recovery.
• Weight Management – maintain BMI < 25 kg/m² to reduce fatty liver stress.
• Exercise – moderate activity (150 min/week) improves liver health.
• Stress Reduction – chronic stress can affect immune modulation; consider mindfulness or yoga.

Psychosocial Support

Experiencing drug‑related liver injury can be frightening. Support groups, counseling, and patient‑education resources (e.g., American Liver Foundation) help reduce anxiety and improve adherence.

Prevention

• Medication Review – have a pharmacist or clinician assess all drugs for hepatotoxic potential before starting new therapy.
• Correct Dosing – never exceed recommended acetaminophen limits (≤4 g/day for adults).
• Alcohol Moderation – limit to ≤1 drink/day for women, ≤2 drinks/day for men.
• Vaccination – hepatitis A & B immunization protects an already vulnerable liver.
• Genetic Testing – in selected cases (e.g., HLA‑B*57:01 before abacavir) to avoid known high‑risk drugs.
• Herbal Supplement Caution – discuss any “natural” products with your provider; many lack safety data.
• Regular Lab Monitoring – baseline LFTs before initiating known hepatotoxins and repeat after 2–4 weeks.

Complications

If not recognized early, drug‑induced hepatotoxicity can progress to serious outcomes:

• Acute Liver Failure (ALF) – rapid loss of synthetic function; mortality 30–50% without transplant.
• Chronic Liver Disease – repeated injury may lead to fibrosis, cirrhosis, and portal hypertension.
• Hepatocellular Carcinoma (HCC) – long‑term cirrhosis increases cancer risk.
• Coagulopathy – prolonged INR → bleeding diathesis.
• Renal Dysfunction – hepatorenal syndrome in severe ALF.
• Neurologic Sequelae – persistent hepatic encephalopathy or cognitive deficits.

When to Seek Emergency Care

References

1. Garcia‑Gonzalez, F.J., et al. “Drug‑Induced Liver Injury: An Overview.” Clin Liver Dis, 2022; 26(2): 173‑186. doi:10.1016/j.cld.2021.12.003
2. World Health Organization. “Global Hepatitis Report 2023.” WHO Press, 2023.
3. Mayo Clinic. “Acetaminophen overdose.” mayoclinic.org. Accessed May 2026.
4. Centers for Disease Control and Prevention. “Drug‑Induced Liver Injury.” cdc.gov. Updated 2024.
5. Cleveland Clinic. “Liver Disease Prevention.” clevelandclinic.org. 2023.
6. U.S. Food & Drug Administration. “Drug-Induced Liver Injury (DILI) Guidance.” 2022.
7. European Association for the Study of the Liver. “EASL Clinical Practice Guidelines: Drug‑Induced Liver Injury.” J Hepatol. 2022; 76(3): 815‑839.

```